Analyst consensus rating
10x Genomics Analyst Rating: Buy
TXG is rated Buy by 13 analysts with a $49.54 target. As of 2026-08-19.
Direct answer
10x Genomics's consensus rating is Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $49.54.
Forecast evidence checked August 19, 2026.
Get free 10x Genomics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $55.63
- Average price target
- $49.54
- High price target
- $65.00
- Low price target
- $40.00
- Low target gap
- -28.1%
- Target upside
- -11%
- High target gap
- +16.8%
- Target range width
- 44.9%
- Consensus rating
- Buy
- Analysts
- 13
- Evidence date
- August 19, 2026
- Valid through
- August 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for 10x Genomics?
10x Genomics has a verified Buy consensus. The same dataset has an average price target of $49.54.
How far are 10x Genomics's low and high targets from the recorded price?
The low target implies -28.1%, while the high target implies +16.8%.
How many analysts are included in 10x Genomics's consensus?
The verified consensus includes 13 analysts.
How is 10x Genomics's target upside or downside calculated?
The average target of $49.54 is divided by the recorded price of $55.63, then one is subtracted to produce -11%. This does not guarantee a future return.
When was 10x Genomics's analyst forecast verified?
The data was verified on 2026-08-19. The dataset is valid through 2026-08-26.